NHS

Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?

1 May 1997

Getting value for money from the use of pharmaceuticals is crucial for the NHS. This publication explores the role for guidelines in generating good quality value for money information examining the experience of Australia, Canada and the UK – the first three health care systems to introduce national guidelines for economic assessments.

Deep Vein Thrombosis and Pulmonary Embolism

10 January 1996

Thrombosis had been recognised as a disease since around 2000 BC, but the word thrombosis was first used by Claudius Galenos (130 – 200 AD). Pulmonary…

The Doctor’s (Ethical and Economic) Dilemma

1 August 1996

In this OHE lecture Professor Sackett sets out a compelling case for evidence-based medicine to be at the core of a comprehensive, tax-funded NHS that enjoys…

Health Care as a Handicraft Industry

9 January 1995

The seemingly inexorable rise in real health care costs (i.e. over and above the rate of inflation) has been a cause of great concern to governments throughout…

Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS

1 January 1995

There is little doubt that throughout the world there is a growing concern about health services and the provision of health care. It is of interest that the worry seems to be independent of the precise structure of health services, the form of provision, and how it is paid for. This suggests two things. One is that the causes of the problem (or problems) are fundamental, and are not entirely, or mainly attributable, to the precise position in any individual country. The second is that each country may have something to learn from the others.

Obesity

1 July 1994

’We are unanimous in our belief that obesity is a hazard to health and a detriment to well-being. It is common enough to constitute one of…

A Doctor Looks at Health Economics

1 March 1994

Inequality in health is back on the political agenda in the UK. Three factors have made inequality an issue – firstly, concern that the internal market…

Managing the NHS: past, present and agenda for the future

1 March 1994

The recent pace of administrative change in the NHS has been rapid, culminating in the October 1993 decision to abolish the Regional tier of management and…

Economic Evaluation of Growth Hormone Therapy

1 December 1991

Treatment of children with growth hormone is well recognised under the NHS and its cost (between £5,000-£10,000 per annum per child) has generally been accepted. Since…